Tag: ageing

  • Anti-obesity drug has life-changing benefits for arthritis

    Anti-obesity drug has life-changing benefits for arthritis

    [ad_1]

    Coloured X-ray of the knees of a patient with severe osteoarthritis, shown in blue and orange colours

    Osteoarthritis, which causes stiff and painful joints, affects the knees most often.Credit: Dr. P. Marazzi/Science Photo Library

    A blockbuster weight-loss drug sharply reduces pain from obesity-related knee arthritis and improves a person’s ability to engage in activities such as walking. That’s according to a clinical trial conducted in 11 countries — the first of its kind to prove that one of the new wave of anti-obesity drugs can treat arthritis. The drug, semaglutide, provided pain relief on a par with opioid drugs.

    At the end of the trial, many participants’ pain had subsided enough that they were no longer eligible for the study, says Henning Bliddal, a rheumatologist at Copenhagen University Hospital at Bispebejerg and Frederiksberg who helped to conduct the trial. “They got a therapy that was so effective that they more or less were treated out of the study,” he says.

    The results are “important and could be helpful” for people with knee osteoarthritis, says Leigh Callahan, an epidemiologist at the University of North Carolina, Chapel Hill.

    The findings were published today in the New England Journal of Medicine1. The trial was sponsored and designed by Novo Nordisk, which is based in Bagsværd, Denmark, and makes semaglutide, a drug sold as Ozempic for treating diabetes and Wegovy for treating obesity. Bliddal served briefly as a paid consultant to the company during trial planning.

    Spreading scourge

    Osteoarthritis, which causes stiff, painful joints, is among the most common conditions of ageing, and the knee is the most frequently affected joint. People who have obesity are at higher risk of developing arthritic knees because they have extra stress on their joints. Obesity also worsens symptoms, Callahan says. Pain from the condition can keep people from exercising, Bliddal says, making it extremely difficult for them to lose weight by lifestyle changes alone.

    The trial enrolled some 400 participants on five continents and randomly assigned them to receive weekly injections of either semaglutide or a placebo. They also received counselling on healthy eating and physical activity. When the trial began, participants had obesity, and their average score on a 100-point pain scale was 71 — high enough that walking was painful.

    After 68 weeks of injections, participants taking semaglutide had lost much more weight than those taking the placebo. They also reported a much bigger drop on the pain scale: an average of 42 points, versus an average of 28 points for placebo recipients. These participants noticed a greater improvement in everyday functioning, such as climbing stairs, too.

    The improvement probably stems in part from a decreased load on the knee stemming from weight loss, the authors write. But semaglutide also has anti-inflammatory effects, which might help to explain the pain relief.

    Despite the benefits, Bliddal is concerned about the long-term outlook for those who use semaglutide to relieve knee arthritis. “Do these guys go on with semaglutide forever” to manage their pain? People who stop taking the drugs generally regain the lost weight, and the medications are expensive — a month’s supply can cost hundreds of US dollars.

    Callahan emphasizes that although the results seem “very exciting”, it’s important for people to supplement anti-obesity drugs with lifestyle changes for long-term weight maintenance.

    [ad_2]

    Source link

  • CRISPR helps brain stem cells regain youth in mice

    CRISPR helps brain stem cells regain youth in mice

    [ad_1]

    Fluorescent light micrograph of groups of neural stem cells shown in pink and yellow colours on a black background

    Brain stem cells (artificially coloured) give rise to neurons in young individuals, but that ability fades with advancing age.Credit: Riccardo Cassiani-Ingoni/Science Photo Library

    Clues to keeping the brain’s regenerative cells youthful and energetic into old age have emerged by applying CRISPR gene editing to mice1.

    Age impedes the ability of the brain’s stem cells to churn out new cells, but the study’s authors found that reducing the activity of a particular gene rejuvenated these stem cells, allowing them to proliferate and provide the brain with a supply of fresh neurons.

    That gene regulates stem cells’ consumption of glucose, a sugar that is key to cellular metabolism. The results in mice fit well with an emerging picture from studies of postmortem human brains. These efforts, too, have found that age affects metabolism in the brain, says Maura Boldrini, a neuroscientist and psychiatrist at Columbia University Irving Medical Center in New York City who was not involved in the latest research. “Probably their metabolism is less efficient than it used to be,” she says, adding that both the human results and the mouse study, published today in Nature, “open new avenues for potential therapeutics.”

    A youthful brain

    The role of neural stem cells in the adult human brain has been controversial. Boldrini and others have published evidence that new neurons are made in the hippocampus, a region of the brain that is important for learning and memory, at least until the age of 792. Her team is now looking to see whether production of new neurons is altered in people with Alzheimer’s disease or psychiatric illnesses. But some researchers have reported that they could not find evidence that adults make new neurons in the hippocampus. “This controversy is still continuing,” Boldrini says.

    In mice, the picture is clearer. Neural stem cells in a region of the brain called the subventricular zone can give rise to neurons and other types of cells. These young cells then migrate to the olfactory bulb, which controls the sense of smell. A steady supply of fresh neurons to the olfactory bulb makes sense in mice, because they rely heavily on smell to perceive changes in their environment, says Anne Brunet, a geneticist who studies ageing at Stanford University in California and who is an author of the new study.

    As mice age, however, those stem cells become less active. Brunet and her colleagues decided to find out why. The team used CRISPR-Cas9 genome editing to systematically disrupt 23,000 genes, and then tested the effect of each disrupted gene on neural stem cells that had been taken from young and old mice and grown in the laboratory.

    Neuronal boost

    The screen yielded 300 genes that might play a part in neural stem-cell ageing. The researchers further narrowed the pool by using CRISPR-Cas9 to disrupt some of these genes in cells in the subventricular zone of living young and old mice. The authors then checked the animals’ olfactory bulbs and identified a select group of key genes. Disruption of these genes boosted stem cells’ production of neurons in the old animals — but did not affect stem cells in young animals.

    One such gene, called Slc2a4, codes for a protein that imports glucose into cells. Disrupting it reduced cells’ glucose intake and increased their power to proliferate.

    That result meshes with previous studies that have found a link between sugar metabolism and ageing, says Saul Villeda, a neuroscientist at the University of California, San Francisco. For example, researchers recently reported that a diabetes drug can stave off age-related cognitive decline in monkeys. But the latest finding is particularly important, he says, because it points to a specific protein that has a key role and could be targeted in future studies.

    Even if the role of neural stem cells in adult humans is in question, the results provide crucial information for the design of cell therapies that might one day treat neurodegenerative conditions, Villeda says.

    [ad_2]

    Source link

  • CRISPR–Cas9 screens reveal regulators of ageing in neural stem cells

    [ad_1]

    Laboratory animals

    Cas9-expressing mice (Cas9 mice) were obtained from the Jackson Laboratory (https://www.jax.org/strain/024858). These mice (background C57BL/6N) constitutively express the Cas9 endonuclease and an eGFP reporter under the control of a CAG promoter knocked into the Rosa26 locus49. All screens in this study were performed with the Cas9 mice, including all NSC primary cultures and all in vivo work. We maintained a colony of Cas9 mice ranging in ages up to 28 months at the Stanford Comparative Medicine Building and the Neuroscience-ChemH building vivarium. As a negative control for the in vivo screens, male C57BL/6 mice obtained from the National Institute on Aging Aged Rodent colony were used at 18–21 months old. These mice were habituated in the Stanford facility for at least 2 weeks before initiation of experiments. Mice were maintained under the care of the Veterinary Service Center at Stanford University under IACUC protocols 8661.

    Primary cultures of NSCs from young and old brains and activation experiments

    For all experiments involving primary culture of NSCs, we pooled SVZs from pairs of male and female Cas9 mice, either 3–4 months old (young) or 18–21 months old (old). To generate primary cultures of NSCs from young and old mice, we microdissected SVZs into a small drop of PIPES buffer (pH 7.4), minced them in a 10 cm tissue culture dish with about 100 chops of a scalpel blade and suspended the tissue in PIPES buffer before centrifugation for 5 min at 300g, at which point the excess PIPES buffer was poured out. The pellet of minced SVZs was then enzymatically dissociated (in 5 ml per 2 SVZs) with a mixture of HBSS (Corning, 21-021-CVR) with 1% penicillin–streptomycin–glutamine (Gibco, 10378-016), 1 U ml–1 Dispase II (StemCell Technologies, 07913), 2.5 U ml–1 papain (Worthington Biochemical, LS003126) and 250 U ml–1 DNAse I (D4527, Sigma-Aldrich), vortexed briefly and incubated at 37 °C for 40 min on a rotator. The samples were then centrifuged at 300g for 5 min at room temperature and resuspended in Neurobasal A medium (Gibco, 10888-022) with 1% penicillin–streptomycin–glutamine (Gibco, 10378-016) and 2% B27 minus vitamin A (Gibco, 12587-010) and triturated about 20 times, centrifuged and resuspended in complete ‘aNSC medium’, comprising Neurobasal A (Gibco, 10888-022) supplemented with 2% B27 minus vitamin A (Gibco, 12587-010), 1% penicillin–streptomycin–glutamine (Gibco, 10378-016), 20 ng ml–1 EGF (Peprotech, AF-100-15) and 20 ng ml–1 bFGF (Peprotech, 100-18B) and placed in a humidified incubator at 37 °C and 5% CO2. After 3–4 days, neurospheres emerged in the medium and were passaged by dissociation with 1 ml Accutase (StemCell Technologies, 07920) for 5 min at 37 °C, washed once with PBS and resuspended in aNSC medium. Neurosphere cultures were maintained with passaging every 2–3 days, and all experiments were performed in cultures of fewer than 10 passages. Details on passage numbers are provided in experimental sections below. For cultures of qNSCs, the aNSC culture medium was changed to remove EGF and to add BMP4 (50 ng ml–1) (Peprotech, 315-27). The Complete ‘qNSC medium’ comprised Neurobasal-A (Gibco, 10888-022) supplemented with 2% B27 minus vitamin A (Gibco, 12587-010), 1× penicillin–streptomycin–glutamine (Gibco, 10378-016), 50 ng ml–1 BMP4 (BioLegend, 94073) and 20 ng ml–1 bFGF (Peprotech, 100-18B). To induce quiescence, tissue culture plates were pre-treated with PBS (Fisher Scientific, MT21040cv) containing 50 ng ml–1 poly-d-lysine (PDL; Sigma-Aldrich, P6407) for 1 h and then washed 3 times with PBS before plating cells on plates in qNSC medium. The density of cells plated is important for induction of quiescence and the ability of qNSCs to reactivate, especially in the context of lentiviral infection. In optimizing the qNSC activation protocol, we observed that qNSCs seeded at the following densities were best for quiescence and activation experiments: 2 × 107 cells for a 15 cm plate; 1 × 106 cells per well for a 6-well plate; 2 × 105 cells per well for a 24-well plate; and 1 × 105 cells per well for a 96-well plate. For activation of qNSC cultures, cells were washed once with PBS, and then aNSC medium was added to the plate and refreshed every 2 days. For plating, cells were manually counted with a haemocytometer or using a Countess II FL Automated Cell Counter (Life Technologies, AMQAF1000). NSC primary cultures were tested quarterly for the presence of mycoplasma and tested negative.

    Tissue culture plastics

    We found that primary cultures of NSCs were sensitive to the tissue culture plastic products used. Specifically, passaging NSCs in conical tubes manufactured by Genesee (15 ml conical tubes, 28-103) resulted in death of the NSC cultures within 1 week of brief exposure to the plastic during passaging. Plastics from the following manufacturers were assessed to be suitable for NSC growth both in detached and adherent conditions: Thermo Fisher 15/50 ml Falcon tubes (14-959-53A/14-432-22), 15 cm, 10 cm, 6-well, 12-well, 24-well and 96-well Falcon tissue culture dishes (353025, 08772E, 08-772-1B, 08-772-29, 08-772-1, 087722c, respectively).

    Lentivirus production

    Genome-wide virus library preparation

    For lentiviral production, we used human embryonic kidney 293T cells. 293T cells were from the American Type Culture Collection (they were not authenticated). They were tested for the presence of mycoplasma in a quarterly manner and tested negative. 293T cells were seeded in DMEM + 10% FBS (Gibco 10099141) + 1× penicillin–streptomycin–glutamine (Gibco, 10378-016) at a density of 2 × 107 cells in 15 cm plates. One day later, 293T medium was replaced with 18 ml fresh medium and the cells were transfected using the polyethylenimine (PEI) (1 mg ml–1, Polysciences, 23966-2) transfection method, mixing plasmids as follows: 2.27 μg each of third-generation lentivirus packaging vectors pMDLg, pRSV and pVSVG (obtained from the laboratory of M. Bassik), along with 45 μg of the pooled sgRNA genome-wide plasmid library (https://www.addgene.org/pooled-library/bassik-mouse-crispr-knockout/). The sgRNA library targets around 23,000 protein-coding genes in the genome, with 10 unique sgRNAs per gene, and15,000 control sgRNAs (about 245,000 sgRNAs in total)29. The sgRNA plasmid library, consisting of 20 sublibraries, was mixed proportionally to the number of sgRNAs in each library. One day after PEI transfection, the medium was changed to 18 ml of Neurobasal A + 1× penicillin–streptomycin–glutamine (Gibco, 10378-016). After 1 day, the viral containing supernatant was collected on ice and stored at 4 °C. Fresh medium was added to the 293T cells and collected again after 24 h and again at 48 h (a total of 3 collections of 18 ml of virus supernatant). All 3 supernatants were combined, filtered through a 0.45 μm filter (Stericup, EMD Millipore, S2HVU02RE) and frozen at −80 °C in 10 ml aliquots in 15 ml conical tubes. For plasmid library re-amplifications, we electroporated 1 μl of 25 ng μl–1 of each library into 50 μl bacteria (Lucigen, 60242-2), with 1.8 kV, 600 Ω and 10 μF in a 0.1 cm cuvette (Gene Pulser Xcell, Bio-Rad, 1652662). After electroporation, we allowed bacteria to recover in Lucigen recovery medium for 2 h in 15 ml conical tubes, shaking at 37 °C. We plated 1 μl of the transformation onto a LB + carbenicillin (100 μg ml–1, Sigma-Aldrich, C9231-1G) agar plate to confirm transformation efficiency, and the remainder of the recovery suspension was placed into 0.5 litre LB + carbenicillin (100 μg ml–1) liquid medium in a 2 litre flask for 16 h of shaking at 37 °C, and DNA was purified using a Maxiprep kit (Thermo Fisher Scientific, FERK0492) according to the manufacturer’s protocol.

    sgRNA sublibrary design

    We designed five sublibraries of sgRNAs to test gene hits from the in vitro screens in the brain in vivo (Figs. 1 and 2). Our selection criteria were as follows. For the top 10 gene list, we selected all significantly enriched genes (FDR < 0.1) from the first 2 in vitro genome-wide screens, selecting any gene that was significant in both screens 1 and 2, at any time point, day 4 or day 14 (for example, a screen 1 day 4 hit and an overlapping screen 2 day 14 hit would be added to the list). With that list, we ranked the genes based on the CasTLE gene score average from both screens and both time points (that is, average of all: screen 1 day 4 or day 14, screen 2 day 4 or day 14). This library was selected based on the first two in vitro genome-wide screens only, because at the time of library design, only the first two in vitro screens had been completed. Similarly, the ‘depleted’ gene list was also selected based on the first two screens. We selected all significantly depleted genes (FDR < 0.1) from the first 2 in vitro genome-wide screens, selecting any gene that was significant in both screens 1 and 2, at any time point, day 4 or day 14 (for example, a screen 1 day 4 hit and an overlapping screen 2 day 14 hit would be added to the list). With that list, we then removed any gene that was significantly (FDR < 0.1) depleted in qNSCs of screen 1 or 2 of any age. The final list was then selected by removing unannotated genes (for example, GM3264 and GM3164) and focusing on genes with associated publications. For the ‘glucose uptake/human disease’ list, we selected genes that were significantly (FDR < 0.1) enriched in 2 out of 3 in vitro genome-wide screens, at day 4 or day 14 (for example, a screen 1 day 4 hit and an overlapping screen 2 day 14 hit would be added to the list). The list of enriched genes was analysed by GO term analysis (see the section ‘Computational analysis of CRISPR screens’). From the GO Molecular Function (2018) database, the d-glucose transmembrane transporter activity (GO:0055056) and sugar:proton symporter activity (GO:0005351) terms were both in the top 10, with genes Slc2a4, Slc2a12 and Slc45a4. The other genes in the ‘glucose uptake/human disease’ list were selected based on one of two criteria: (1) genes implicated in human disease: Snrpb2 (Alzheimer’s disease)85, Sorl1 (Alzheimer’s disease)86 and C1qtnf5 (human ageing)87; or (2) genes that are significantly (P < 0.05) upregulated in qNSCs in old mice: Slit2 (refs. 25,88), Ier2 (ref. 25), Cdkn1a25,88 and Ecscr25. For the ‘cytoplasmic ribonucleoprotein granules’ library, in the GO term analysis of gene knockouts that boosted old NSC activation, the terms P-body (GO:0000932), cytoplasmic ribonucleoprotein granule (GO:0036464), ribonucleoprotein granule (GO:0035770) and cytoplasmic stress granule (GO:0010494) all came up in the list, although most were not significant. From this, we proposed that cytoplasmic granule structures could impede old NSC activation. We took the entire GO term cytoplasmic ribonucleoprotein granule (GO:0036464) and selected gene knockouts that had the greatest difference in effect between young and old NSC screens. Many of these genes did not demonstrate any significant effect in our in vitro screens, other than Dis3l2, Edc3 and Mbnl1, which all significantly boosted old NSC activation in at least two out of three screens. The final list of genes was the ‘published NSC regulators’ list, which we chose based on searching the literature for genes that had previously been implicated in regulation of NSC function and behaviour. We did not select based on functional effect prediction.

    sgRNA plasmid sublibrary cloning for in vivo screens

    The sgRNA expressing plasmid MCB320 (https://www.addgene.org/89359/) was digested with the BlpI and BstXI restriction enzymes, the band was gel-extracted and purified and used for a pooled ligation reaction. We selected five sgRNAs from each gene of interest, based on the five out of ten sgRNAs most enriched or depleted in our genome-wide in vitro screen. For the forward oligonucleotide of each sgRNA sequence, we added the following sequences: 5′-ttgg and 3′-gtttaagagc. For the reverse complement oligonucleotide of each sgRNA sequence, we took the reverse complement of the sgRNA sequence and added 5′-ttagctcttaaac and 3′-ccaacaag. To clone a pool of 10 genes, we selected the 50 sgRNAs pairs targeting the 10 genes and annealed the sgRNA pairs in separate annealing reactions in a 100 μl of IDT duplex buffer (11-05-01-12) with 1 µM forward and reverse oligonucleotides. We incubated the oligonucleotide pairs at 95 °C for 5 min and then allowed the oligonucleotides to gradually anneal at room temperature. We mixed all 50 annealed oligonucleotide pairs into one pool, diluted it 1:20 in IDT duplex buffer and then used 1 μl of annealed oligonucleotide pool in a ligation reaction with 500 ng of digested MCB320 backbone. We used 1.5 μl of the ligation mix and electroporated 30 μl competent bacteria (Lucigen, 60242-2) with 1.8 kV, 600 Ω and 10 μF in a 0.1 cm cuvette (Gene Pulser Xcell, Bio-Rad, 1652662). We plated the entire recovered transformed bacteria on a 10 cm LB + ampicillin (100 μg ml–1, Sigma-Aldrich, A9518-100G) plate, allowed overnight recovery, and the next day added 5 ml LB to the bacterial lawn and scraped it with a sterile silicon scraper. The resuspended bacterial mix was transferred to a clean collection tube, the plate was again rinsed with an additional 5 ml LB and transferred to same tube for overnight growth in 500 ml LB + ampicillin (100 μg ml–1) for Maxiprep (Thermo Fisher Scientific, FERK0492) according to the manufacturer’s protocol. For library re-amplification, we performed the same transformation and amplification procedure.

    Concentration of virus for in vivo and in vitro subscreens

    For in vivo and in vitro subscreens, we generated virus the same way as our genome-wide virus libraries but with modifications. We plated four 15 cm plates of 293T cells for a total of 200 ml of collected virus after 3 days of collecting at 4 °C, but rather than directly freezing the virus, we performed ultracentrifugation to concentrate the virus. For ultracentrifugation, we sterilized 30 ml ultraclear tubes (Beckman Coulter 344058) under UV (TC room biosafety cabinet) for 15 min. We then put the tubes on ice, allowed 15 min to cool and then added 30 ml of virus and centrifuged at 16,500 r.p.m. for 1 h at 4 °C. We carefully decanted the supernatant using serological pipettes, leaving 1 ml medium in the bottom of the tube, adding 30 ml more virus-containing medium and centrifuging again. We repeated the decanting, refilling and centrifugation of the same tube, concentrating a total of 180 ml of virus supernatant into a single tube. After the last ultracentrifugation, we removed most of the supernatant with a serological pipette, and the last 1 ml with a P1000 pipet tip from the side of the tilted tube, so as not to disturb the viral pellet. The viral pellet was usually visible in centre of all of the tubes. We resuspend in 60 μl ice-cold PBS (1/3,000th original volume) by pipetting up and down about 60 times, being careful not to produce air bubbles. The concentrated resuspended virus was then aliquoted into PCR strip tubes in 5 μl aliquots and placed onto dry ice. After 15 min, the virus was transferred to −80 °C for storage. For experiments, virus was thawed on ice and injected into the brain or added to cell culture within 30 min of thawing. We assessed virus infectivity of each batch by performing serial dilution (3 μl, 1 μl, 0.5 μl) infections of 2 × 105 293T cells in 24-well culture plates for 16 h of infection and then performing FACS analysis 48 h later to detect the per cent of cells expressing the mCherry reporter. For each experiment, we normalized virus infectivity (viral titre) across treatments by adjusting the concentrations of virus added in PBS.

    Genome-wide knockout screens in primary cultures of NSCs

    For each genome-wide screen, primary cultures of NSCs derived from a pool of three male and three female Cas9 mice were used for each independent biological replicate. In total, three independent genome-wide screens, each performed with independent young and old NSC pooled from six mice, were conducted. For each independent screen, young and old NSC cultures were processed in parallel at each stage of sample processing. The young and old NSC culture passage numbers were kept the same and at the start of screen were as follows: screen 1, passage 8; screen 2, passage 7; screen 3, passage 12. To measure the growth rates of young and old cells at each passage, we counted cells using a Countess 3 cell counter (Thermo Fisher, A50298). The young and old cells showed comparable growth rates (Extended Data Fig. 1c). To expand the NSCs up to 1.4 × 109 cells (the equivalent of 140 15 cm plates) required for each biological replicate, 1 × 107 NSCs were passaged and expanded into 15 cm plates every 2–3 days, with feedings every 2 days (alternating between doubling the medium (with 2× growth factor aNSC medium) or complete medium exchange). For each screen, 70 plates of 2 × 107 qNSCs were seeded at day 0 (see below for library coverage calculations). After 4 days in qNSC medium, the cells were incubated with the genome-wide sgRNA lentivirus library (see above). For this, the sgRNA lentivirus library was freshly thawed at room temperature and diluted 1:5 in Neurobasal medium and then B27 and growth factors were added to make it qNSC medium, and 18 ml of this mix was added to plates for 16 h of overnight infection. The virus dilution added was based on viral titration experiments determined to achieve about 30% culture infection of cells to ensure each cell only received a single sgRNA. Therefore, infecting the starting 1.4 × 109 cells at 30% infection would result in 4.2 × 108 infected cells, giving us a coverage of about 1,700 cells per sgRNA (around 243,000 total sgRNAs). Note that these numbers represent the starting library coverage, but the cells do expand over the course of activation; therefore, the final cell numbers at end of experiment are orders of magnitude larger. The infected cells were then left in qNSC medium for an additional 5 days before transition to aNSC medium for activation. After 4 days of activation, the cells were dissociated using Accutase (Stem Cell Technologies, 07920) for 15–30 min at 37 °C (until most cells rounded up) and gently scraped with silicone cell scrapers (Fisher Scientific, 07-200-364) and split into 2 groups: 55 plates of NSCs were processed for the day 4 Ki67 FACS sorting (see below), and the other 15 plates of cells were placed into aNSC culture for 10 days of further expansion as neurospheres (day 14 timepoint). The day 4 FACS-sorted young and old cells were sorted to have equal numbers of Ki67+ cells from both ages for each screen for downstream analysis. See the section ‘Intracellular FACS’ below for day 4 FACS protocol. The final number of sorted cells for each age in each screen was as follows: screen 1 had 2.2 × 107 sorted Ki67+ cells; screen 2 had 1.41 × 107 Ki67+ cells; and screen 3 had 1 × 108 Ki67+ cells. After sorting, the methanol-fixed cells were centrifuged at 700g for 5 min, the supernatant FACS buffer was decanted and the cell pellets were frozen at −80 °C until genomic DNA extraction. To extract genomic DNA of sorted and methanol-fixed cells, the cell pellets were defrosted at room temperature and then processed by resuspending in 5 ml of TE 1% SDS (Thermo Fisher Scientific, 15525017) and incubated at 65 °C for 16 h. The cell suspension was then treated with 50 μl proteinase K (Fisher Scientific, 25-530-049)(20 mg ml–1) for 2 h at 37 °C. Samples were processed for genomic DNA extraction using Zymo Research ChIP DNA clean and concentrator (Zymo, D5205) according to manufacturer’s protocol. The day 14 expanding neurospheres were immediately centrifuged at 300g for 5 min and then processed for genomic DNA extraction with a Qiagen QiaAmp DNA Blood Maxi kit (51194), adding 5 × 107 cells per column and according to the manufacturer’s protocol.

    sgRNA PCR amplification and sequencing

    After genomic DNA isolation, sgRNA was amplified from the genome in two successive, nested PCR reactions. For the nested PCR reactions, we used either Herculase II Fusion polymerase (Agilent, 600679) for screen 1 or Q5 DNA polymerase (Fisher Scientific, M0491L) for screens 2 and 3, and Q5 DNA polymerase for in vivo screens, according to the manufacturer’s protocol. In optimizing this PCR reaction, we found that Herculase II polymerase was outperformed by Q5 polymerase, with Q5 polymerase requiring fewer PCR cycles to obtain more amplicon product, which is why we switched to Q5 DNA polymerase. We used 5 μg genomic DNA in 50 μl reactions to run on a thermocycler. For the first PCR, we used primers MCB1562 (aggcttggatttctataacttcgtatagcatacattatac) and MCB1563 (acatgcatggcggtaatacggttatc) (1 µM final concentration), with PCR cycles as follows: 98 °C for 2 min, 19 cycles of (98 °C for 30 s, 59.1 °C for 30 s, 72 °C for 45 s), followed by 72 °C for 3 min. We pooled all the PCR 1 cycle products and then used 5 µl of the pool in a second PCR reaction (PCR 2) with the same conditions but using different primers: MCB1439 (caagcagaagacggcatacgagatgcacaaaaggaaactcaccct) and a barcoded primer (aatgatacggcgaccaccgagatctacacGATCGGAAGAGCACACGTCTGAACTCCAGTCACXXXXXXCGACTCGGTGCCACTTTTTC, where XXXXXX is the 6-digit barcode for high-throughput sequencing sample identification). The second PCR reaction was run for either 30 cycles (in vitro screen 1 and in vivo screens) or 18 cycles (in vitro screens 2 and 3). The resulting PCR products were all resolved on a 1.5% DNA agarose gel. The 272 bp band was extracted (Qiaquick Gel extractions kit, 28706), eluted in 10 μl ultrapure water (Invitrogen, 10977023) and assessed on a bioanalyzer (Agilent, Bioanalyzer 2100). Final libraries were combined into a pool at equal concentrations for sequencing on an Illumina Novaseq S4 system (by Novogene for the genome-wide in vitro screen) or on an Illumina MiSeq system (by the Stanford Genomics Facility for in vivo screens), sequencing to a depth of about 1 × 107 or 5 × 105 reads per sample for in vitro and in vivo screens, respectively.

    Computational analysis of CRISPR–Cas9 screens

    For both the in vitro and in vivo screens, our analyses were performed using the CasTLE pipeline28. All of the source scripts can be found at Bitbucket (https://bitbucket.org/dmorgens/castle/downloads/). In brief, for each screen, the raw screen fastq files were aligned to the sgRNA library sequence (mm-Cas9-10 or one of a custom 10 gene library + control sgRNAs) to make count files using the makeCounts script. The count files were then analysed using the analyzeCounts CasTLE script, comparing each screen timepoint to the starting plasmid sgRNA library count file (in vitro screens) or the sequenced 24-h SVZ count file (in vivo screens), which we sequenced in parallel with screen libraries. We then calculated P values for all genes in each screen by running 100,000 (in vitro screens) or 10,000 (in vivo screens) permutations with the addPermutations CasTLE script. For each genome-wide screen, we corrected for multiple hypotheses on the around 23,000 gene associated P values using the Python Statsmodel module, with the Benjamini–Hochberg method, and classified genes as significant using a FDR < 0.1 cut-off. For the in vivo screens, we classified genes as hits if their CasTLE computed 95% confidence interval did not contain 0. The library diversity of each sample was displayed using the plotDist CasTLE script. The screen results and individual gene sgRNA enrichment plots were visualized using the plotVolcano and plotGene scripts, respectively. We note that in in vivo screens, there was a bimodal distribution of control sgRNAs, which is most likely due to the fact that a control sgRNA infected a NSC that was, at the time, highly actively proliferating and that will naturally enrich in the olfactory bulb.

    Generation of gene lists for the genome-wide screens

    To generate the final gene lists for the genome-wide screens, we used all genes that were significant (FDR < 0.1) in 2 or more independent screens (screens 1 and 2, 2 and 3, or 1 and 3), at any time point (day 4 or day 14; for example, a screen 1 day 4 hit and an overlapping screen 2 day 14 hit, would be added to the list). For PCA, we used the Python sklearn.decomposition.PCA module with CasTLE-computed gene scores as input (Fig. 1d and Extended Data Fig. 1g–i). We performed gene set enrichment analysis by inputting gene lists into the EnrichR online portal (https://maayanlab.cloud/Enrichr/)89,90, and then focusing on the ‘Ontologies’ tab with GO Biological Process (2018), Molecular function (2018) and Cellular components (2018), sorting the terms based on P value, which is computed by EnrichR using the Fisher exact test.

    Assessment of potential outliers in the genome-wide screens

    To test for potential outliers, we compared CasTLE scores for all genes in the genome-wide screen between each replicate at day 14 for the young NSC screens (Extended Data Fig. 1d–f). Correlations between replicates were calculated using Spearman’s correlation test. We also examined the principal component (PC) loadings of day 14 young and old in vitro genome-wide screens (PC1 and PC2) and day 4 young and old in vitro genome-wide screens (PC3 and PC4). PC loadings were extracted using the Python sklearn.decomposition.PCA module. We performed gene set enrichment analysis by inputting the top 50 gene knockouts contributing to the PC into EnrichR online portal (https://maayanlab.cloud/Enrichr/)89,90, and then focusing on the ‘Ontologies’ tab with GO Biological Process (2018), Molecular function (2018) and Cellular components (2018), sorting the terms based on P value, which is computed by EnrichR using the Fisher exact test. The PC loadings and the GO terms are included in Supplementary Table 4. The GO terms of the genes that contribute to the replicate young 1 at day 14 not clustering with the other young replicates are enriched for cytosolic proteasome complex (GO:0031597) and proteasome-activating ATPase activity (GO:0036402). As mentioned above in the section ‘Generation of gene lists for the genome-wide screens’, we chose hits from the screen that were significant in two or three replicates to avoid having one of the screens skew the data. We also investigated the loading of all PCs for both day 4 and day 14 and performed GO term analysis on the genes underlying all PCs (Supplementary Table 4). Genes and GO terms underlying the technical variance for day 4 samples (PC1, PC2 and PC4) are involved in cell division, proteostasis and transcription/translation. Thus, one possible source of variance in this in vitro NSC system could be due to lentiviral infection (affecting cell survival/cell proliferation) or bottlenecking during passaging.

    Comparison with published screens and databases

    We tested whether the genes significantly depleted at the day 14 timepoint overlapped with a list of common essential genes. We generated a list of day 14 significantly (FDR < 0.1) depleted genes in both the young and old screens (Supplementary Table 1). We identified the overlap between significantly depleted genes in the NSC screens with the Core Essential Genes 2 list91 and the Online GEne Essentiality database (https://v3.ogee.info/#/home)92 (Extended Data Fig. 1l,m). P values were calculated using a Fisher’s exact test. There was a small but significant overlap between the known essential gene lists and the significantly depleted NSC gene list. Thus, these in vitro genome-wide screens captured essential genes that are shared with published datasets but also captured unique genes for which knockout affected cell survival or activation in NSCs.

    Intracellular FACS for Ki67

    For the genome-wide screen and for other qNSC activation experiments, we FACS-isolated proliferative cells (Ki67+) as follows. Cells were dissociated with Accutase (StemCell Technologies, 07920) for 5 min, collected into conical tubes and centrifuged at 300g for 5 min. Cells were resuspended in PBS at 5 × 107 cells in 1 ml (or 1 × 105 cell in 100 μl), and then 9 ml (or 900 μl) ice-cold 100% methanol was added and cells were agitated for 15 min at 4 °C. Cells were then centrifuged at 500g for 5 min and resuspended for a wash in 3 ml PBS and centrifuged again at 500g for 5 min. Cells were then resuspended in 3.5 ml staining solution: Ki67-APC (eBioscience, 17-5698-82) 1:300 in PBS, 2% FBS (Gibco, 10099141) at 4 °C. Samples were agitated for 30 min at room temperature in the dark, and then 10 ml PBS was added before centrifugation at 700g for 5 min. Samples were then resuspended (25 ml per 5 × 107 cells) in FACS buffer: PBS, 2% FBS, DAPI (Fisher Scientific, 62248, 1 mg ml–1) 1:5,000. Each sample was filtered with FACS-strainer cap tubes (Fisher, 08-771-23), immediately before FACS sorting. Cells were sorted on an Aria BD FACS Aria with a 100 μm nozzle at 13 p.s.i., with BD FACSDiva software (v.8.0.1), and FlowJo (v.10) software was used for data analysis.

    Assessment of NSC activation for in vitro subscreen and glucose intervention

    For testing the top 10 gene library (in vitro subscreen) (Fig. 1e) and glucose intervention (Fig. 4i), we performed qNSC activation experiments in a 24-well or 96-well format. We seeded 2 × 105 cells in a 24-well format or 1 × 105 cells in a 96-well format. After 4 days in qNSC medium, with medium changes every 2 days, concentrated virus was then added to the cells. We added 3 μl equal titre virus (see the section ‘Concentration of virus for in vivo and in vitro subscreens’) to each 24-well containing 500 μl qNSC medium, or 0.1 μl virus to 100 μl in each 96-well experiment. We left the virus in medium with cells for 16 h, and then refreshed the medium. At 5–6 days after infection, the cells were washed 1× in PBS and then either transitioned to aNSC medium for activation (Fig. 1e) or incubated with qNSC medium with or without glucose for 2 days and then transitioned to aNSC medium for activation (Fig. 4i). aNSC medium was exchanged once after 48 h and Ki67 intracellular FACS was performed at day 4 after infection (see the section ‘Intracellular FACS’ above). Even though overall activation was decreased in lentivirally infected cells compared with non-infected cells, the difference in activation between old and young NSCs was preserved.

    Assessment of the impact of individual gene knockout on NSC activation

    To test the impact of individual gene knockouts on NSC activation (Fig. 1j), we used 8 independent NSC cultures from old (18–21 months old) mice, each culture being a mix of 1 male and 1 female mouse. We infected these NSC cultures with purified lentiviruses expressing five sgRNAs per gene. We evaluated the top 10 genes (screens 1 and 2) (Supplementary Table 3). To assess the effect of each individual gene knockout on NSC activation, we seeded 3 × 105 NSCs in a 24-well format. After 4 days in qNSC medium, with medium changes every 2 days, qNSCs were incubated with fresh lentiviruses with equal titre. Lentiviruses were generated as described in the section ‘Lentivirus production’ using 293T cells. For these experiments, lentiviruses expressing sgRNAs to individual genes were collected by incubating 293T cells directly in qNSC medium. The supernatants were collected and their titres were tested, using serial dilutions to achieve a similar 50–70% range of infection of 293T cells. Supernatants were added to the qNSC wells for 16 h, and then the medium was changed to qNSC medium. Six days after infection, the cells were washed 1× in PBS and then transitioned to aNSC medium for activation. aNSC medium was exchanged once after 48 h and then Ki67 intracellular FACS was performed at day 3 after infection (see the section ‘Intracellular FACS’ above).

    Validation of individual knockout efficiency

    We validated the knockout efficiency for seven individual genes in qNSC cultures in two independent experiments:

    For experiment 1, young and old NSCs were seeded in a 24-well PDL pre-coated plate at a density of 2–3 × 105 cells per well and incubated in qNSC medium. After 4 days with medium changes every 2 days, qNSCs were infected with lentiviruses expressing sgRNAs targeting each gene (5 sgRNAs per gene) as described in the section ‘Assessment of the impact of individual gene knockout on NSC activation’ (see Source Data Extended Data Fig. 1n for sgRNA sequences). Six days after infection, cells were washed with PBS then lysed directly with DirectPCR Lysis reagent (Viagen Biotech, 102-T) with 1% Proteinase K (Fisher Scientific, 25-530-049) for 10 min at room temperature. The supernatant was pipetted repeatedly, then transferred to PCR strip tubes and incubated at 65 °C for 25 min, and then 95 °C for 15 min in a thermocycler. We amplified genomic DNA with primer pairs surrounding the sgRNA-editing sites (see Source Data Extended Data Fig. 1n for amplification primers), using Q5 polymerase (Fisher Scientific, M0491L) and the following program: 30 s of annealing step at 55 °C and 1 min of extending step at 72 °C for 40 cycles total.

    For experiment 2, we cloned 5 sgRNAs for each individual gene, using the same methodology as described in the section ‘sgRNA plasmid sublibrary cloning for in vivo screens’ above. For lentiviral production, 293T cells were seeded in DMEM + 10% FBS (Gibco 10099141) + 1× penicillin–streptomycin–glutamine (Gibco, 10378-016) at a density of 13 × 106 cells in 15 cm plates. One day later, 293T medium was replaced with 18 ml fresh medium and the cells were transfected using the PEI (1 mg ml–1, Polysciences, 23966-2) transfection method. The individual gene library (25.5 µg) was transfected together with the lentiviral packaging plasmids psPAX2 (32.12 µg) and pCMV-VSV-G (9.44 µg) per 15 cm plate. psPAX2 was a gift from D. Trono (Addgene, plasmid 12260; http://n2t.net/addgene:12260; RRID:Addgene_12260). pCMV-VSV-G was a gift from B. Weinberg (Addgene, plasmid 8454; http://n2t.net/addgene:8454; RRID:Addgene_8454). One day (20–24 h) after transfection, the medium was changed to Neurobasal A with penicillin–streptomycin–glutamine. After another 20–24 h, lentivirus containing supernatant was collected and stored at 4 °C and fresh medium was added to the 293T cells for another collection after 24 h. Both supernatants were then combined, filtered through a 0.45 µm polyvinylidene fluoride filter (Millipore Sigma, SE1M003M00) and frozen at −80 °C in 5 ml aliquots. For lentiviral transduction, young qNSCs were plated onto 6-well PDL pre-coated plates at a density of 1.75 × 106 cells per well (for control lentivirus), 10 cm PDL pre-coated plates at the density of 1.0 × 107 cells per plate (for Slc2a4-targeting lentivirus) or 12-well PDL pre-coated plates at a density of 4.0 × 105 cells (for Npb and B3galnt2 targeting lentivirus). NSCs were kept in qNSC medium for 4 days (with medium changes every other day) before transduction. After removing medium, viral supernatants (2 ml for 6-well plates, 10 ml for 10 cm plates and 1 ml for 12-well plates) were thawed at room temperature and mixed with 8% of B27 minus vitamin A, bFGF (80 ng ml–1) and BMP4 (200 ng ml–1). qNSCs were incubated with lentiviral medium for 24 h. After removing lentiviral medium after 24 h, a second lentiviral transduction was repeated the next day. After two consecutive transductions, qNSCs were washed once with Neurobasal A medium and then cells were kept in qNSC medium for 7 days to allow recovery and CRISPR editing. To select for a population of cells that was infected by the lentivirus, 1.0 μg ml–1 of puromycin (Sigma-Aldrich, P8833) was added to the cultures for 3 days, with medium changes every day. To assess knockout efficiency, we isolated genomic DNA as described above for experiment 1. We amplified genomic DNA with primer pairs roughly 150–250 bp upstream and 300–450 bp downstream of sgRNA editing site (see source data for list of primers) using GoTaq Green master mix (Promega, M7123) and the following amplification program: 30 s of annealing step at 55 °C and 1 min of extending step at 72 °C for 40 cycles total.

    In both experiment 1 and experiment 2, PCR amplicons were Sanger sequenced using the respective forward primers (source data). We then analysed knockout efficiency using the DECODR (v.3.0) online tool (https://decodr.org/)93. Each sgRNA was analysed separately, and the editing efficiency is indicated in source data. Individual sgRNAs that had an editing efficiency with a r2 value less than 0.6 from DECODR (v.3.0) are indicated as low confidence (LC) in source data and marked with a hash symbol in Extended Data Fig. 1n. Individual sgRNAs that were not detected by DECODR (v.3.0) in the Sanger sequencing trace are indicated as not detected (ND) in source data and not included as data points in Extended Data Fig. 1n. Finally, we note that the percentage of knockout per gene is probably also underestimated due to the fact that larger indels that span sgRNA cutting sites are not taken into account by DECODR.

    In vivo gene knockout experiments

    Stereotaxic surgeries were performed to inject virus into the lateral ventricle of mice. For these experiments, old Cas9 mice were used, except for one experiment for which old wild-type mice were used (see the section ‘Laboratory animals’). Surgeries were performed on heating pads with isoflurane-induced anaesthesia, with a Kopf (Model 940) stereotaxic frame, World Precision Instruments (UMP3T-1) UltraMicroPump3, Hamilton 1710RN 100 μl syringe with 30 g Small Hub RN needle with a point 2 bevelled end. Injections were made at the following coordinates, relative to bregma: lateral 1 mm, anterior 0.3 mm and ventral depth 3 mm from the skull surface. After drilling the skull and inserting the needle into position, we waited 5 min before injecting the virus. We injected 3 µl of equal titre virus at a rate of 10 nl s–1. We waited 7 min after injection before removing the needle and suturing the skin. Animals were administered a single dose of buprenorphine SR (0.5 mg kg–1) for postoperative pain management and monitored for 1 week after surgery until full recovery. For labelling of proliferating NSC progeny, we injected animals intraperitoneally weekly with EdU (Thermo Fisher Scientific, A10044, 50 mg kg–1, dissolved in sterile PBS), starting 1 week after surgery. We used both male and female mice for in vivo testing, always making a note of the sex for each experiment. We did not observe major differences in results between sexes, and plots include data from both sexes.

    Influence of the anaesthetic

    In our pilot experiments, we performed some surgeries with ketamine–xylazine anaesthesia instead of isoflurane for the relative ease of use, which we consider resulted in marked impairment of neurogenesis in both young and old animals when assessed in downstream screen analyses. In brief, we performed our in vivo screening as outlined above, but we could detect only very few sgRNAs in the olfactory bulb 5 weeks after injection when the mice had been anaesthetized with ketamine–xylazine. We interpreted the lack of sgRNA detection in the olfactory bulb as an indication that not many NSCs were able to activate and migrate to the olfactory bulb in those conditions. We repeated the experiments with ketamine–xylazine 2 times, in around 20 animals, always observing an impairment in sgRNA detection in the olfactory bulb after 5 weeks. When the same virus was injected into same age and background mice under isoflurane anaesthesia, we detected a greater diversity and abundance of sgRNAs in the olfactory bulb 5 weeks later. We therefore did not perform any surgeries presented in this article with ketamine–xylazine anaesthesia, but used isoflurane instead.

    At the end point of in vivo experiments, mice were either killed for sequencing of sgRNAs in the brain (in vivo subscreens) or for immunofluorescence imaging (see the section ‘In vivo immunofluorescence experiments’) of the olfactory bulb and other brain regions (single gene knockout experiments). For sequencing sgRNAs in the brain, mice were killed either 1–2 days after injection or 5 weeks after injection and their brains were immediately removed and subdissected for genomic DNA extraction. We used a scalpel to cut off the olfactory bulbs and to cut an approximately 1 mm thin slice of the outer cortex as well as the outer cerebellum. We then subdissected out the SVZ niche. We took each tissue and minced it with around 100 cuts of a scalpel and proceeded to extract genomic DNA according to the manufacturer’s protocol (Qiagen QIAamp DNA micro kit, 56304). The genomic DNA was then processed for sgRNA amplification and sequencing as outline in the section ‘sgRNA PCR amplification and sequencing’.

    Immunofluorescence staining of brain sections, image analysis and quantification

    Brain sections in the olfactory bulb and SVZ

    For immunofluorescence straining of brain sections, young and old anaesthetized mice were first subjected to intracardiac perfusion with 4 ml of heparin (Sigma Aldrich, H3149-50KU) and then 25 ml 4% paraformaldehyde (PFA) (Electron Microscopy Science, 15714) in PBS. Brains were then removed and further fixed for 16 h by submerging in 4% PFA at 4 °C. Brains were then washed 3 times in PBS and placed in a conical tube with a 30% sucrose (Sigma-Aldrich, S3929-1KG) in PBS solution for 2–3 days until sinking to bottom of conical tube. The brains were then embedded in optimal cutting temperature (OCT) compound (Electron Microscopy Sciences, 62550-12) for cryosectioning. Brain coronal sections were taken at 20 µm thickness (Leica, CM3050S). For assessing neurogenesis in the olfactory bulb, every tenth section was used. Thus, imaging was performed every 200 µm across the entire olfactory bulb. For assessing different cell types in the SVZ, we began taking sections at the most anterior part of the lateral ventricle, and every tenth section was used. Thus, imaging was performed every 200 µm across the SVZ.

    Immunofluorescence staining of brain sections

    For immunofluorescence staining, sections were brought to room temperature and then washed once with PBS and then permeabilized with ice-cold methanol and 0.1% Triton X-100 (Fisher Scientific, BP151) for 15 min. All samples were stained at the same time. Slides were washed 3 times with PBS and then treated with ClickIt reagents (for EdU) or put straight into antibody blocking solution. For Click-It EdU staining (Thermo Fisher Scientific, C10337/C10639/C10634), we placed 50–70 µl of reaction cocktail from this kit onto the tissue and incubated in humidified chamber at room temperature for 30 min. Slides were then washed 3 times in PBS before blocking for antibodies. Slides were treated with 50–70 µl blocking solution (5% normal donkey serum (NDS, ImmunoReagents, SP-072-VX10), 1% BSA (Sigma-Aldrich, A1595-50ML), 8.5 ml PBS) in a humidified chamber at room temperature for 30 min. Blocking solution was replaced with antibody solution consisting of blocking solution with antibodies as follows: mCherry (Invitrogen, M11217, clone 16D7) 1:500, GFAP (Abcam, 53554) 1:500, GFP (Abcam, 13970) 1:500, GLUT4 (for in vivo staining R&D Systems, MAB1262, clone 1F8) 1:500, Ki67 (Invitrogen, 14-5698-082, clone SolA15) 1:500, STX4A (Santa Cruz Biotechnology, sc-101301, clone QQ-17) 1:500, GFP (Abcam, 13970) 1:500, mouse IgG (Santa Cruz SC-3877, lot: L1916) 1:500, NeuN (Millipore, MAB377 clone A60) 1:500, S100a6 (Abcam, ab181975, clone EPR13084-69) 1:500, Tuj1 (BioLegend, 802001) 1:500, Olig2 (R&D Systems, AF2418) 1:100, Sox10 (Abcam, Ab180862, clone EPR4007-104) 1:100, calretinin (Abcam, Ab244299) 1:500, Dcx (Cell Signaling Technology, 4604) 1:500. We tested two mCherry antibodies (Abcam, ab213511 clone EPR20579; Invitrogen, M11217 clone 16D7) and we found that Invitrogen, M11217 was better for immunostaining for brain sections. After primary staining in dark for 2 h in humidified chamber at room temperature or 16 h at 4 °C, slides were washed 3 times in PBS before staining with secondary antibodies. Secondary antibodies were diluted in blocking solution and consisted of Alexa 488/594/647 conjugated antibodies (Fisher Scientific, A21202, A21206, A21209, A21447, A31571, A31573) 1:500, and DAPI (1 mg ml–1, Fisher Scientific 62248) 1:5,000. We added 50–70 µl of secondary antibody mix to cover the section and incubated in the dark for 2 h in a humidified chamber at room temperature or 16 h at 4 °C. Slides were then washed 3 times with PBS 0.2% Tween for 10 min, washed 3 times with PBS for 5 min and then mounted using ProLong Gold (20–40 µl, Thermo Fisher Scientific, P36931), dried for 2 h and sealed with nail polish. To allow for quantification of the immunofluorescence staining, we paid special attention to stain all the brain sections from different groups (for example, young and old) in the same way and at the same time.

    Confocal imaging of immunofluorescence staining in brain sections

    Images were captured using a Zeiss LSM 900 confocal microscope with a ×10, ×20 or ×63 objective, with Zen blue edition (v.3.0). The exposure and gain settings for each channel and antibody were set at the beginning of each imaging session and remained the same for all animals and treatments. We randomized the order in which we imaged the slides and we ensured that different treatments and age groups were all imaged in the same session on the same day. The imaging was not performed in a blinded manner. We did not select areas to image. We imaged and quantified serial sections. Confocal imaging was done every 200 μm across the entire olfactory bulb or SVZ region.

    Image analysis and quantification of immunofluorescence staining in brain sections

    For image analysis, we used the open-source software QuPath (https://qupath.github.io/)94. This approach allowed us to set the thresholds and quantification parameters on training images and then ran the same analysis across all sections, samples and treatments in an automated manner. Many cells (>100 cells per section in vivo) and many sections (>50 sections per age group in vivo) were counted in an unbiased manner using an automated pipeline (in QuPath).

    Quantification of GLUT4 depletion efficiency in the SVZ niche by immunostaining in vivo

    For quantifying GLUT4 depletion efficiency in the SVZ niche, we first annotated a polygonal line around the SVZ NSC niche, creating an analysis region about 5–20 cells deep from the ventricle wall. We then performed the ‘analyse→cell detection’ function, detecting cells in the image based on DAPI staining, using the program default settings, expanding the cell nuclei 5 µm in the ‘cell parameters’ section. We then trained two independent object classifications for GFAP+ and mCherry+ cells, adjusting the thresholds to detect positive cells that were apparent by eye. We combined the GFAP+ and mCherry+ objects into a single composite classifier and ran it on all annotated images and treatments. The results were output as annotation detections. The annotation detections were used to display the GLUT4 channel cell mean fluorescence intensity for GFAP+mCherry+ compared with GFAP+mCherry populations in the different treatments.

    Quantification of newborn neurons in the olfactory bulb by immunostaining in vivo

    For quantification of newborn neurons in the olfactory bulb, we first annotated a polygon line immediately beneath the olfactory bulb mitral cell layer to focus the analysis within the inner layers of the olfactory bulb, where newborn neurons arrive. We then performed the ‘analyse→cell detection’ function, detecting cells in the image based on DAPI staining, using the program default settings, expanding the cell nuclei 5 µm in the ‘cell parameters’ section. We then trained three independent object classifications for mCherry+, EdU+ and NeuN+ cells, adjusting the thresholds to detect positive cells that were apparent by eye. We combined the mCherry, EdU and NeuN objects into a single composite classifier and ran it on all annotated images and treatments. The results were output as annotation measurements and annotation detections. The annotation measurements were used for graphs depicting the number of NeuN+mCherry+EdU+/total EdU+ cell numbers for each treatment, and the annotation detections were used to display the NeuN channel cell mean fluorescence intensity for EdU+mCherry+ populations in the different treatments.

    Quantification of different cell numbers in the SVZ niche by immunostaining in vivo

    For quantifying different cell numbers in the SVZ niche with Slc2a4 sgRNA treatment compared with control, we first annotated a polygonal line around the SVZ NSC niche, creating an analysis region about 5–20 cells deep from the ventricle wall. We then performed the ‘analyse→cell detection’ function, detecting cells in the image based on DAPI staining, using the program default settings, expanding the cell nuclei 5 µm in the ‘cell parameters’ section. We then trained three independent object classifications for GFAP+, Ki67+ and S100a6+ cells, adjusting the thresholds to detect positive cells that were apparent by eye. We combined the GFAP+, Ki67+ and s100a6+ objects into a single composite classifier and ran it on all annotated images and treatments. The results were output as annotation measurements. The annotation measurements were used for graphs depicting the sgRNA treatment and impact on number of each cell type: qNSCs (GFAP+S100a6+Ki67), aNSCs (GFAP+S100a6+Ki67+), neuroblasts (GFAPKi67+) and astrocytes (GFAP+S100a6) for each condition.

    Quantification of GLUT4 protein levels in different cell types of the SVZ niche by immunostaining in vivo

    For quantification of GLUT4 fluorescence intensity in different cell types of young and old mice in vivo, we first annotated a polygonal line around the SVZ NSC niche, creating an analysis region about 5–20 cells deep from the ventricle wall. We then performed the ‘analyse→cell detection’ function, detecting cells in the image based on DAPI staining, using the program default settings, expanding the cell nuclei 5 µm in the ‘cell parameters’ section. We then trained two independent object classifications for Ki67+ (or S100a6+, for NSC specific labelling experiments) cells and GFAP+ cells, adjusting the thresholds to detect positive cells that were apparent by eye. We combined the Ki67 (or S100a6) and GFAP objects into a single composite classifier and ran it on all annotated images and treatments. The results were output as annotation detections. The annotation detections were used to display the GLUT4 channel cell mean fluorescence intensity for GFAP+Ki67+ (aNSCs), GFAP+Ki67 (qNSCs/astrocytes), GFAPKi67+ (neuroblasts), GFAPKi67 (other cells, including ependymal and microglia) or GFAP+S100a6+ (NSCs) populations across different aged mice. The GLUT4 antibody we used for immunostaining of brain sections (R&D Systems, MAB1262, clone 1F8) was validated in vivo by the Slc2a4 knockout (see above).

    For all experiments, the output numbers displayed on the graphs were derived from the average of all serial section images across a biological replicate (one mouse), biological sample values were then analysed for significance by two-tailed Mann–Whitney test.

    Immunofluorescence staining of primary cell cultures of NSCs and quantification

    Immunofluorescence staining of NSC cultures

    For immunofluorescence staining of primary cell cultures of NSCs, we seeded 2.5 × 105 aNSCs or 2 × 105 qNSCs onto PDL (50 ng ml–1, Sigma-Aldrich, P6407) pre-treated (30 min, followed by 3× PBS wash) coverslips in each well of a 24-well plate. The qNSCs were plated 7 days before fixation, the aNSCs were plated 24 h before fixation. For fixation, cells were washed once with PBS and then 500 μl of 4% PFA (Electron Microscopy Science, 15714) was added for 30 min of incubation at room temperature. Cells were washed 3 times with PBS and then permeabilized with 0.1% Triton X-100 (Fisher Scientific, BP151) in PBS for 15 min shaking at room temperature. Coverslips were washed twice with PBS and then processed for antibody staining. Coverslips were placed on a 45 µl drop of primary antibody solution consisting of 1% BSA in PBS with primary antibodies as follows: GLUT4 (Abcam, 33780) 1:500, Ki67 (Invitrogen, 14-5698-082) 1:500, STX4A (Santa Cruz Biotechnology, QQ-17) 1:500. After 1 h of incubation in the dark at room temperature, slides were washed 3 times in PBS shaking for 5 min at room temperature. Slides were then placed on 45 µl drop of secondary antibodies in 1% BSA in PBS consisting of Alexa 488/594/647 conjugated antibodies (Fisher Scientific, A21206, A21209, A31571) 1:500, and DAPI (1 mg ml–1, Fisher Scientific 62248) 1:5,000. After 1 h of incubation at room temperature in the dark, slides were washed 3 times with PBS before mounting with ProLong Gold, dried for 2 h and sealed with nail polish. To allow quantification of immunofluorescence staining, we paid special attention to stain all coverslips in the same way and at the same time.

    Confocal imaging of immunofluorescence staining in NSC cultures

    Images were captured using a Zeiss LSM 900 confocal microscope with a ×10, ×20 or ×63X objective. The exposure and gain settings for each channel and antibody were set at the beginning of each imaging session and remained the same for all samples and treatments. We randomized the order in which we imaged the slides, and we ensured that different treatments and age groups were all imaged in the same session on the same day. The imaging was not done in a blinded manner. We did not select areas to image. We randomly selected ten areas of each coverslip to image. For image analysis, see the section ‘Immunofluorescence image analysis’.

    Image analysis and quantification of immunofluorescence staining in NSC cultures

    For image analysis, we used the open-source software QuPath (v.0.2.3) (https://qupath.github.io/)94. This approach allowed us to set the thresholds and quantification parameters on training images and then ran the same analysis across all sections, samples and treatments in an automated manner. For the in vitro GLUT4 and STX4A quantifications, we selected the entire image as the analysis annotation. We then performed the ‘analyse→cell detection’ function, detecting cells in the image based on DAPI staining, using the program default settings, expanding the cell nuclei 5 µm in the ‘cell parameters’ section. The results were output as annotation detections. The annotation detections were used to display the GLUT4 and STX4A cell mean fluorescent intensity for each protein’s channel in each cell culture type and age group. For all experiments, the output numbers from different images were averaged across a biological replicate (one NSC culture), biological sample values were then analysed for significance by two-tailed Mann–Whitney test. We note that the age-dependent increase in GLUT4 and STX4A proteins was not large in qNSC cultures. In addition, we were not able to detect significant changes in Slc2a4 by RT–qPCR and western blotting in young and old qNSCs. This lack of detection is probably due to sensitivity issues: single-cell RNA sequencing and immunofluorescence staining are single-cell-based assays, which can be more sensitive than bulk assays (such as RT–qPCR and western blotting) in capturing small differences in transcript or protein expression.

    Expression of glucose transporter genes and fatty acid oxidation gene signature in single-cell RNA sequencing

    To test the expression of Slc2a4 and other glucose transporter genes, we retrieved the raw counts from our most recent single-cell RNA sequencing dataset from the SVZ neurogenic niche from young and old mice70 and used a subset of the data containing only the control (sedentary) animals across young and old ages (i.e. O_Control and Y_Control in the AgeCond metadata column). We normalized the counts data by dividing each cell by its total expression, scaling up to 105 total counts per cell, and then taking the log-transform of the normalized counts with an added pseudocount. For comparisons across cell types, we used the pre-existing cell-type annotations: Astrocyte_qNSC, aNSC_NPC and Neuroblast70. For comparisons across age, we compared old (O_Control) and young (Y_Control) animals using the pre-existing age annotations in the dataset70. For statistical comparisons of the mean expression across conditions, we used the two-sample Welch’s t-test from stat_compare_means(). Welch’s t-test is designed for unequal population variances. To compute the log fold change, we divided the average expression in the old cells by the average expression in young cells and then took the log2-transform of the resulting ratio. To compute the fatty acid oxidation gene signature, we summed the expression of the 19 genes from the fatty acid oxidation signature published in ref. 95 for each cell in the published single-cell RNA sequencing dataset from SVZ neurogenic niches of young and old mice70. We then compared the fatty acid oxidation gene signature levels across old and young qNSCs/astrocytes using the two-sample Welch’s t-test, which is designed for unequal population variances.

    Expression of Slc2a4 RNA in bulk RNA sequencing (in vitro)

    To test the expression of Slc2a4 in vitro, we retrieved the RNA sequencing normalized counts from in vitro qNSCs and aNSCs from a published dataset51. To calculate significance between qNSCs and aNSCs, we used a two-sided Mann–Whitney test.

    Glucose uptake assays

    For qNSCs, we seeded 40,000 cells per well and for aNSCs we seeded 10,000 cells per well (aNSCs do not stick to the plate as well and will double every 16–24 h, so we seeded fewer cells to achieve similar density to qNSCs at the time of analysis) on PDL (Sigma-Aldrich, P6407) pre-coated 96-well plates, performing the assay 3 days after seeding. Duplicate wells were seeded and used for cell count normalization at time of glucose uptake assay. For knockout experiments, 1 × 105 qNSCs were plated per well on PDL pre-coated 96-well plates in qNSC medium 6 days before infection with lentivirus to express sgRNA, for which 1 μl of concentrated virus was added to the culture medium for 16 h to achieve about 100% infection of the cells. We then assessed glucose uptake either 4 days or 8 days after infection using two different types of assays (see below).

    Colorimetric glucose uptake assay

    For the colorimetric glucose uptake assay (Glucose Uptake-Glo Assay, Promega, J1342; Fig. 4f,h), experiments were performed according to the manufacturer’s protocol, with the following details. Cells were pre-treated for 1 h of qNSC/aNSC culture medium without glucose. Culture medium was then replaced with 50 µl of qNSC/aNSC medium containing 1 mM 2-DG (provided in the Glucose Uptake-Glo kit from Promega (J1342)) reagent for 10 min in an incubator (humidified, 37 °C, 5% CO2). The 2-DG medium was then removed and 50 µl of PBS was added before carrying out the remainder of the assay according to the manufacturer’s protocol. All media treatments and reagent exchanges were pre-aliquoted into an empty 96-well plate, such that we could add the treatment to entire rows of cells at once using a multi-channel pipette to ensure that the duration of treatment was equivalent across different cell types and ages. The luminescence of the cells was measured with 0.5 s readings using a Varioskan LUX multimode plate reader. Owing to different treatments having effects on cell numbers, plate readings in some cases (mentioned in figure legends) required normalization to the cell counts (Countess II cell counter, Thermo Fisher Scientific) based on duplicate wells. We performed glucose uptake experiments on different numbers of NSCs and observed a linear correlation between relative light units and cells plated.

    Fluorescent glucose uptake assay

    For the fluorescent 2-NBDG glucose uptake assay (fluorescent 2-NBDG [2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-deoxyglucose] (Fisher, N13195; Extended Data Fig. 6f), cells were placed in glucose-free medium for 1 h and then treated with 200 µM 2-NBDG for 30 min at 37 °C, and then analysed by flow cytometry at excitation/emission maxima of around 465/540 nm, with DAPI added in the medium to eliminate dead cells.

    Assessing GLUT4 depletion efficiency at the protein level in vitro

    Western blot to assess GLUT4 depletion efficiency at the protein level

    Young aNSCs were seeded onto PDL-coated 10 cm plates at a density of 1 × 107 cells per plate and transferred into qNSC medium. Medium was changed every 2 days. After 4 or 5 days in qNSC medium, qNSC cultures were infected with lentivirus expressing control sgRNAs or Slc2a4 sgRNAs (5 sgRNAs). Seven days after infection, 1.0 μg ml–1 puromycin (Sigma-Aldrich, P8833) was added to the cultures for 3 days, with medium changes every day, to select for infected cells. Then, the cells were washed with PBS and incubated on ice with ice-cold 1× lysis buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 0.5% sodium deoxycholate and 0.5% Triton-X 100) and 1× protease inhibitor (Thermo Fisher Scientific, 87786) for 10 min and cells were scraped off of the plate. Lysates were centrifuged at 10,000g for 10 min at 4 °C. The supernatant was removed and preserved, then the protein concentration was quantified using a BCA assay (Thermo Fisher Scientific 23225). To load the samples, 4× LDS buffer (Invitrogen NP007) with 1 mM DTT (Sigma-Aldrich 10197777001) was added to lysates with equal concentrations of protein and the mix was incubated at 95 °C for 7 min; 25 μg of protein was added to each lane. Proteins were separated by SDS–PAGE in MOPS buffer (Invitrogen NP0001) on precast 4–12% Bis-Tris polyacrylamide gels (InvitrogenNP0323BOX). Proteins were transferred onto nitrocellulose membranes. Membranes were incubated for 30 min at room temperature in blocking buffer (PBS + 3% w/v non-fat dry milk + 0.2% Tween-20). Given that GLUT4 and the loading control (β-actin) have a similar molecular weight, we performed western blotting in a sequential manner (first GLUT4 and then β-actin). Primary antibodies to GLUT4 (1:500, Invitrogen PA1-1065) were diluted in blocking buffer and incubated overnight at 4 °C. After three washes in PBS + 0.2% Tween-20, goat anti-rabbit 800CW (1:10,000, Li-Cor 925-32211) in blocking buffer were incubated for 1 h at room temperature and washed 3 times in PBS + 0.2% Tween-20. Detection was performed on a Li-Cor Odyssey FC imaging system with the 800 channel for 10 min. Then primary antibodies to β-actin (1:40,000, Abcam ab6276) as a loading control were added for 1 h at room temperature and washed 3 times in PBS + 0.2% Tween-20. Goat anti-mouse 680CW (1:10,000, Li-Cor 925-68070) in blocking buffer was incubated for 1 h at room temperature and washed 3 times in PBS + 0.2% Tween-20. Detection was performed on a Li-Cor Odyssey FC imaging system with the 700 channel for 30 s. We used ImageJ to quantify the intensity of the GLUT4 and β-actin bands, and the intensity of the GLUT4 band was divided by the intensity of the corresponding β-actin band for each sample. We note that we used different GLUT4 antibodies used for immunofluorescence and western blot experiments because the GLUT4 antibodies used for immunofluorescence did not work for western blotting. This is most likely due to the fact that proteins are in their native form in immunofluorescence experiments but are denatured in western blot experiments. Both GLUT4 antibodies for immunofluorescence and western blotting were both validated using Scl2a4 (GLUT4 knockout) (Fig. 3a–d and Extended Data Fig. 6j).

    FACS to assess GLUT4 depletion efficiency at the protein level

    We plated NSCs on PDL-coated 24-well plates at the density of 3 × 105 cells per well and added qNSC medium for 4 days. After 4 days in quiescence, lentivirus expressing control sgRNAs or sgRNAs to Slc2a4 (5 sgRNAs) was added to qNSCs for overnight infection, and the cells were kept in qNSC medium for another 6 days. After 6 days (to leave time for infection and knockout to occur), the cells were dissociated with Accutase and placed in 500 μl of medium in a 24-well format. FACS was performed by mixing the primary GLUT4 antibody (R&D Systems, MAB1262) at a 5:1 ratio with secondary anti-IgG AlexaFluor647 for 10 min on ice, in the dark. The antibody mix was added to live cells in culture at a dilution factor of 200× (502.5 μl total volume) and incubated in a cell culture incubator (37 °C, 5% CO2) for 30 min. The cells were then fixed by adding 500 μl of PBS + 1% PFA to each well, without shaking the cells. Cells were incubated at room temperature for 20 min in the dark, and then analysed by FACS (BD, LSRFortessa). FACS quantification was done by gating first on mCherry+ cells (infected cells).

    ECAR and OCR

    To measure ECAR and OCR, we seeded 80,000 NSCs into qNSC medium in a PDL pre-treated well of a 96-well plate. The cells were maintained in quiescence for 4 days with medium exchanges at 24 and 72 h after seeding. The cells were then treated with unconcentrated equal titre lentivirus (with control sgRNAs or sgRNAs to Scl2a4) for 16 h of overnight infection. The cells were placed back into qNSC medium for 48 h before running the metabolic assay. For ECAR, assays were run according to manufacturer’s protocol (Glycolysis assay, Abcam, Ab197244), with the following parameters. The cells were placed in a CO2-free incubator at 37 °C for 3 h before running the assay. Fluorescence was measured using a Tecan Spark plate reader with the following settings: instrument was pre-warmed to 37 °C 1 h before the run, the run mode parameters were as follows: kinetic, kinetic duration 90 min, interval time 1 min and 30 s, excitation wavelength 380, excitation bandwidth 20, emission wavelength 615, emission bandwidth 10. The slope of the fluorescence detected over the period of linear increase was calculated for each sample. For OCR, assays were run according to the manufacturer’s protocol (Extracellular Oxygen Consumption Assay, Abcam, Ab197243) with the following parameters. The extracellular O2 consumption reagent was used at 1/15 dilution (10 µl added to 150 µl of sample in a 96-well plate). High-sensitivity mineral oil was pre-warmed to 37 °C 30 min before use, and 2 drops were used for each well before running the assay on plate reader. Fluorescence was measured using a Tecan spark plate reader with following measurements: excitation 380 ± 20 nm, emission 650 ±  20 nm, kinetic duration 1 h and 30 min, interval time 1 min and 30 s. The slope of the fluorescence detected over the period of linear increase was calculated for each sample.

    Transient glucose starvation

    NSCs were placed in qNSC medium for 4 days, exposed to lentivirus to express sgRNAs targeting Slc2a4 or unannotated genomic regions (control). Then 6 days after infection, the cell medium was replaced with standard complete qNSC medium with glucose or modified to have no glucose (Neurobasal A medium, Thermo Scientific, A2477501, no d-glucose, no sodium pyruvate, supplemented with 1× sodium pyruvate, Fisher Scientific, 11-360-070) for 48 h, at which point the medium was replaced with standard complete aNSC medium (with normal glucose concentration (4,500 mg l–1) in Neurobasal A medium, Thermo Fisher 10888-022) and the cells were allowed to activate for 4 days before intracellular FACS analysis with Ki67.

    Effect of 2-DG on young and old NSC activation

    To test the effect of 2-DG on young and old NSC activation, we performed qNSC activation experiments in a 24-well plate format. Primary cultures of NSCs were derived from a pool of 2 young (3–4 months old) or old (18–21 months old) mice (1:1 mix of male and female). We seeded 2 × 105 NSCs in each well of a 24-well plate. After 4 days in qNSC medium (with qNSC medium changes every 2 days), 2-DG (2 mM final concentration, Sigma, D8375) was added to the medium for 36 h of treatment, with one exchange at the 24-h time point. After 36 h of treatment, the cells were washed 1× in PBS and then transitioned to aNSC medium for activation. aNSC medium was exchanged once after 48 h and then Ki67 intracellular FACS was performed at day 4 after treatment to assess NSC activation efficiency as described above. P values were determined by two-tailed Mann–Whitney test.

    Statistical analyses

    We did not perform randomization, but for all experiments, young and old conditions were processed in an alternate manner rather than in two large groups to minimize the group effect. We did not perform power analyses, although we did take into account previous experiments to determine the number of animals needed. To calculate significance for experiments, all tests were two-sided Mann–Whitney tests, unless otherwise indicated. Results from individual experiments and all statistical analyses are included in the source data.

    Reporting summary

    Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

    [ad_2]

    Source link

  • Axolotls seem to pause their biological clocks and stop ageing

    Axolotls seem to pause their biological clocks and stop ageing

    [ad_1]

    Axolotls appear to age very little over their lifetimes

    SeaTops / Alamy

    Ever wished you could hit the pause button on ageing? At least one creature may do just that. Axolotls seem to halt one of the hallmarks of the process part way through their lives, a finding that could shed new light on ageing and regeneration.

    Axolotls (Ambystoma mexicanum) belong to a group of amphibians called salamanders, which are famed for their astonishing powers of regeneration, such as regrowing amputated limbs. They also appear to age very little, a feature called negligible senescence.

    [ad_2]

    Source link

  • The brain aged more slowly in monkeys given a cheap diabetes drug

    The brain aged more slowly in monkeys given a cheap diabetes drug

    [ad_1]

    Close-up of a long-tailed macaque taking a nap on a rock

    Cellular measures of ageing changed more slowly in the liver, brain and other tissues of monkeys taking the drug metformin.Credit: Vachira Vachira/NurPhoto/Getty

    A low-cost diabetes drug slows ageing in male monkeys and is particularly effective at delaying the effects of ageing on the brain, finds a small study that tracked the animals for more than three years1. The results raise the possibility that the widely used medication, metformin, could one day be used to postpone ageing in humans.

    Monkeys that received metformin daily showed slower age-associated brain decline than did those not given the drug. Furthermore, their neuronal activity resembled that of monkeys about six years younger (equivalent to around 18 human years) and the animals had enhanced cognition and preserved liver function.

    This study, published in Cell on 12 September, helps to suggest that, although dying is inevitable, “ageing, the way we know it, is not”, says Nir Barzilai, a geroscientist at the Albert Einstein College of Medicine in New York City, who was not involved in the study.

    Medicine-cabinet staple

    Metformin has been used for more than 60 years to lower blood-sugar levels in people with type 2 diabetes — and is the second most-prescribed medication in the United States. The drug has long been known to have effects beyond treating diabetes, leading researchers to study it against conditions such as cancer, cardiovascular disease and ageing.

    Data from worms, rodents, flies and people who have taken the drug for diabetes suggest the drug might have anti-ageing effects. But its effectiveness against ageing had not been tested directly in primates, and it is unclear whether its potential anti-ageing effects are achieved by lowering blood sugar or through a separate mechanism.

    This led Guanghui Liu, a biologist who studies ageing at the Chinese Academy of Sciences in Beijing, and his colleagues to test the drug on 12 elderly male cynomolgus macaques (Macaca fasciucularis); another 16 elderly monkeys and 18 young or middle-aged animals served as a control group. Every day, treated monkeys received the standard dose of metformin that is used to control diabetes in humans. The animals took the drug for 40 months, which is equivalent to about 13 years for humans.

    Over the course of the study, Liu and his colleagues took samples from 79 types of the monkeys’ tissues and organs, imaged the animals’ brains and performed routine physical examinations. By analysing the cellular activity in the samples, the researchers were able to create a computational model to determine the tissues’ ‘biological age’, which can lag behind or exceed the animals’ age in years since birth.

    Slowing the clock

    The researchers observed that the drug slowed the biological ageing of many tissues, including from the lung, kidney, liver, skin and the brain’s frontal lobe. They also found that it curbed chronic inflammation, a key hallmark of ageing. The study was not intended to see whether the drug extended the animals’ lifespans; previous research has not established an impact on lifespan2 but has shown lengthened healthspan3 — the number of years an organism lives in good health.

    This means that metformin can “effectively rewind organ age” in monkeys, Liu says. The authors also identified a potential pathway by which the drug protects the brain: it activates a protein called NRF2, which safeguards against cellular damage triggered by injury and inflammation.

    This study is the “most quantitative, thorough examination of metformin action that I’ve seen beyond mice”, says Alex Soukas, a molecular geneticist at Massachusetts General Hospital in Boston. “It was a surprise to see how comprehensive [the drug’s] effects were across tissue types.”

    Low-cost drug, high-cost trial

    Although these results are encouraging, much more research will be necessary to study the drug before it’s validated as an anti-ageing compound in humans, Liu says.

    For one, only 12 monkeys received the drug. Soukas says he would therefore like to see a replication of this effort or a study that includes more animals. Furthermore, the researchers tested only male animals, which Rafael de Cabo, a translational geroscientist at the National Institute on Aging in Baltimore, Maryland, says is concerning. He acknowledges that it is extremely expensive to run this type of long-term experiment, but adds that it is crucial to understand ageing in females as well, given that there are often large differences between the sexes.

    In the meantime, Liu and his colleagues have launched a 120-person trial in collaboration with the biopharmaceutical company Merck in Darmstadt, Germany, which developed and manufactures metformin, to test whether the drug delays ageing in humans.

    Barzilai has even bigger ambitions: he and his colleagues have been spearheading an effort to raise US$50 million to study the drug in a trial of 3,000 people aged 65–79 over 6 years. Research into metformin and other anti-ageing candidates could one day mean that doctors will be able to focus more on keeping people healthy for as long as possible rather than on treating diseases, he says.

    [ad_2]

    Source link

  • Menopause age shaped by genes that influence mutation risk

    Menopause age shaped by genes that influence mutation risk

    [ad_1]

    Nature, Published online: 11 September 2024; doi:10.1038/d41586-024-02665-2

    By mining large-population genetic data sets, researchers identify the key factors controlling menopause timing, and reveal a close connection between reproductive longevity, cancer risk and new mutations in children.

    [ad_2]

    Source link

  • Eggs from older mice regain youth when grown in young cells

    Eggs from older mice regain youth when grown in young cells

    [ad_1]

    Light micrograph of a human oocyte in follicle, at completion of the first meiotic division.

    In mammalian ovaries, immature eggs, called ooctyes, develop in follicles.Credit: Don W. Fawcett/Science Photo Library

    Growing immature eggs from old mice in the ovarian structures of young mice can reverse signs of ageing in the eggs1.

    “Think of this as a five-star anti-ageing spa for the old egg,” says Rong Li, a cell biologist at the National University of Singapore (NUS), who co-authored a study describing the results.

    When the rejuvenated eggs were fertilized, the resulting embryos were almost four times more likely to give rise to healthy pups than the eggs that matured in the old environment. The results are published in Nature Aging today.

    Animated sequence from a video showing the procedure for generating reconstituted chimeric follicles.

    Researchers use a pipette to remove an oocyte from its follicle and insert a donor oocyte, which then matures.Credit: HaiYang Wang et al./Nature Aging

    In mammalian ovaries, ovarian structures, known as follicles, house a maturing egg, called an oocyte. Once developed, these pop out as eggs, ready for fertilization. But with age, the number and quality of oocytes decline. Researchers have investigated the role of oocyte ageing in infertility2, but Li and her colleague Wang HaiYang, also a cell biologist at NUS, focused on ageing follicles.

    The latest study offers the “first solid, strong evidence” that follicles can improve the quality of maturing eggs, says Suzannah Williams, an ovarian biologist at the University of Oxford, UK. They’ve “done a fantastic job”.

    Old to young

    The researchers swapped out oocytes from 14-month-old mice that were close to becoming infertile and placed them into the follicles of 2-month-old mice, which were in their reproductive prime — and vice versa.

    They found that the quality of old oocytes improved when grown in young follicles compared with those grown in old follicles. Specifically, after the youthful treatment, the oocytes had fewer chromosomal abnormalities, improved mitochondrial function and their gene expression and metabolite-production profiles better resembled those of young oocytes.

    Meanwhile, young oocytes grown in old follicles showed increased signs of ageing.

    The researchers fertilized the eggs and transferred them into surrogate mice. Embryos that came from rejuvenated oocytes were significantly more likely to give rise to a pup than old oocytes grown in old follicles. However, the success rate didn’t reach that of pups that arose from young oocytes grown in young follicles.

    The results suggests that oocyte ageing is partially reversible, and that the surrounding cellular environment plays an important part in the process, says Li.

    More connections

    The researchers took a closer look at what could be driving oocyte revival. Tunnel-like structures that connect follicles to oocytes, known as transzonal projections (TZPs), pump important molecules for nourishing oocytes. The researchers found a higher density of TZPs in old oocytes embedded in young follicles compared with those embedded in old follicles.

    If the findings translate to people, Li suggests that this could lead to cell therapies that improve egg quality in older people.

    But Williams says that this translation will be tricky, given the difficulties of acquiring sufficient donor tissue and growing them for long enough in the laboratory. Still, she says “it’s a proof of concept”.

    [ad_2]

    Source link

  • How a new kind of vaccine could lead to the eradication of Alzheimer’s and dementia

    How a new kind of vaccine could lead to the eradication of Alzheimer’s and dementia

    [ad_1]

    A businessman uses a broom to sweep up a mess of tangled scribbled lines.

    “I have really modest goals. I want to have the largest impact on human suffering of anyone, ever,” says Lou Reese, co-founder of biotechnology company Vaxxinity. He might just pull it off. If everything goes to plan, by 2030 the firm will offer a new drug that will revolutionise our approach to one of the world’s most feared diseases, and may even lead to its eradication.

    That disease is Alzheimer’s, the most common form of dementia, which causes untold pain to people and their relatives. It and other forms of dementia are seen as a ticking time bomb ready to blow up in the brains of an increasingly elderly population.

    But now it seems there may be a way to defuse this problem. Vaxxinity, which is based in Cape Canaveral, Florida, is working on vaccines designed to halt the progression of Alzheimer’s or even stop it from developing in the first place. Several other companies are in the same game and the approach is showing great promise. “Society is entering an era in which the unchecked devastation of Alzheimer’s disease is no longer inevitable,” says Dennis Selkoe at Harvard Medical School.

    Around 55 million people are living with dementia and that number is projected to rise to about 140 million by 2050, with disastrous consequences for patients, their families and our health and social care systems.…

    [ad_2]

    Source link

  • What accelerates brain ageing? This AI ‘brain clock’ points to answers

    What accelerates brain ageing? This AI ‘brain clock’ points to answers

    [ad_1]

    fMRI scan of a healthy human brain at rest shown in red, yellow and blue colours on a black background

    A functional magnetic resonance imaging scan (artificially coloured) of a human brain. Researchers used data from such scans to measure an aspect of brain ageing.Credit: Mark and Mary Stevens Neuroimaging and Informatics Institute/Science Photo Library

    A newly devised ‘brain clock’ can determine whether a person’s brain is ageing faster than their chronological age would suggest1. Brains age faster in women, countries with more inequality and Latin American countries, the clock indicates.

    “The way your brain ages, it’s not just about years. It’s about where you live, what you do, your socioeconomic level, the level of pollution you have in your environment,” says Agustín Ibáñez, the study’s lead author and a neuroscientist at Adolfo Ibáñez University in Santiago. “Any country that wants to invest in the brain health of the people, they need to address structural inequalities.”

    The work is “truly impressive”, says neuroscientist Vladimir Hachinski at Western University in London, Canada, who was not involved in the study. It was published 26 August in Nature Medicine.

    Only connect

    The researchers looked at brain ageing by assessing a complex form of functional connectivity, a measure of the extent to which brain regions are interacting with one another. Functional connectivity generally declines with age.

    The authors drew on data from 15 countries: 7 (Mexico, Cuba, Colombia, Peru, Brazil, Chile and Argentina) that are in Latin America or the Caribbean and 8 (China, Japan, the United States, Italy, Greece, Turkey, the United Kingdom and Ireland) that are not. Of the 5,306 participants, some were healthy, some had Alzheimer’s disease or another form of dementia and some had mild cognitive impairment, a precursor to dementia.

    The researchers measured participants’ resting brain activity — that when they were doing nothing in particular — using either functional magnetic resonance imaging (fMRI) or electroencephalography (EEG). The first technique measures blood flow in the brain, and the second measures brain-wave activity.

    The authors computed the functional connectivity of each person’s brain and input those data into two deep-learning models trained to predict brain age, one for fMRI data and one for EEG data. They could then calculate each person’s ‘brain-age gap’ — the difference between their chronological age and their brain age estimated from functional connectivity. Having a brain age gap of ten years, for example, would mean that your brain connectivity is roughly the same as that of someone ten years older than you.

    Unequal gaps

    The models showed that people with Alzheimer’s or another type of dementia had larger brain-age gaps than both those with mild cognitive impairment and healthy controls.

    Participants from Latin American or the Caribbean had larger brain-age gaps, on average, than did those from other regions. Latin America is one of the most unequal region in the world, says Ibáñez, and he thinks that this is why the brains of people from that region aged faster. Structural socioeconomic inequality, exposure to air pollution and health disparities were linked to larger brain-age gaps, especially in people from Latin America.

    Moreover, women living in countries with high gender inequality — particularly those in Latin America and the Caribbean — tended to have larger brain-age gaps than did men in those countries.

    Other clocks, other continents

    Simply quantifying brain ageing in a sample this geographically diverse is a phenomenal achievement, says Hachinski. He thinks the conclusion that brain-age gaps vary is solid, but he cautions that functional connectivity is only one way of measuring the health of the brain, and that someone could have a lot of brain connectivity while having, for example, poor mental health due to conditions such as depression or anxiety. Neuroscience is “not good at measuring gestalts”, he says.

    One possible source of inconsistency in the data is the range of fMRI machines and EEGs — spread across 15 nations — that supplied the brain scans. For example, lower-income nations might have had older equipment that generated lower-quality data than those from higher-income nations. But Ibáñez found no association between lower data quality and either a larger brain-age gap or higher structural inequality.

    Now, Ibáñez’s team is investigating whether brain-age gaps are linked to national income by comparing brain-age gaps in groups from Asian nations and the United States, and adding data from ‘epigenetic’ clocks that measure biological age by examining chemical modifications on DNA. Eventually, Ibáñez hopes that the data will contribute to personalized-medicine approaches that are grounded in the full biological diversity of people’s brains around the world.

    “We need to understand this diversity,” says Ibañez. “We cannot create a truly global science of dementia without addressing this.”

    [ad_2]

    Source link

  • Can ageing be stopped? A biologist explains

    Can ageing be stopped? A biologist explains

    [ad_1]

    Download Nature hits the books 22 August 2024

    For millennia, humanity has obsessed about halting ageing and, ultimately, preventing death. Yet while advances in medicine and public-health have seen human life-expectancy more than double, our maximum lifespan stubbornly remains around 120 years.

    On the latest episode of Nature hits the books, Nobel laureate Venki Ramakrishnan joins us to discuss what scientists have learnt about the molecular processes underlying ageing, whether they can be prevented, and why the quest for longevity also needs to consider the health-related issues associated with old age.

    Why We Die: The New Science of Ageing and the Quest for Immortality Venki Ramakrishnan Hodder (2024)

    Music supplied by Airae/Epidemic Sound/Getty images.

    Never miss an episode. Subscribe to the Nature Podcast on Apple Podcasts, Spotify, YouTube Music or your favourite podcast app. An RSS feed for the Nature Podcast is available too.

    [ad_2]

    Source link